Gynaecological and IVF procedures billed through the Medicare Benefits Schedule (MBS) during the COVID-19 pandemic.

BACKGROUND: In response to the COVID-19 pandemic in Australia, restrictions to elective surgeries were implemented nationwide. AIMS: To investigate the response to these restrictions in elective gynaecological and In vitro fertilisation (IVF) procedures during the first wave of the COVID-19 pandemic.
MATERIALS AND METHODS: We analysed the Medicare Item Reports for the number of elective gynaecological (labioplasty, vulvoplasty; prolapse and continence; operative hysteroscopy; hysterectomy; fertility) and IVF procedures claimed in Australia between January-June 2020 and compared these to January-June 2019.
RESULTS: The number of included gynaecological and IVF procedures performed in January-June 2020 decreased by -13.71% and -12.56%, respectively, compared to January-June 2019. The greatest reductions were in May 2020 (gynaecology -43.71%; IVF -51.63% compared to May 2019), while April 2020 reported decreases of -37.69% and -31.42% in gynaecological and IVF procedures, respectively. In April 2020, 1963 IVF cycle initiations (-45.20% compared to April 2019), 2453 oocyte retrievals (-26.99%) and 3136 embryo transfers (-22.95%) were billed. The procedures with greatest paired monthly decrease were prolapse and continence surgeries in April (676 procedures; -51.85%) and May 2020 (704 procedures; -60.05%), and oocyte retrievals in May 2020 (1637 procedures; -56.70%).
CONCLUSIONS: While we observed a decrease in procedural volumes, elective gynaecological and IVF procedures continued in considerable numbers during the restricted timeframes. In the event of future overwhelming biological threat, careful consideration must be given to more effective measures of limiting access for non-emergency procedures to conserve essential resources and reduce risk to both the public and healthcare staff.

Introduction

In response to the coronavirus disease 2019 (COVID‐19) pandemic in Australia, restrictions to elective surgeries were implemented nationwide to mitigate patient and staff risk, ensure adequate hospital capacity, and preserve personal protective equipment. From 25 March, 2020, all elective surgeries and procedures were suspended in public and private hospitals nationally, with the exception of Category 1 (clinically indicated within 30 days) and some exceptional Category 2 procedures (clinically indicated within 90 days). , This decision was supported by The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), who recommended restricting surgeries to Category 1 procedures only. This included: assessment and treatment of suspected or proven gynaecological malignancy; miscarriage, ectopic pregnancy and termination of pregnancy; acute haemorrhage and acute‐on​‐chronic pelvic pain failing medical management; acute pelvic pain; and continued access to current contraceptive methods. Following containment of spread of COVID‐19, elective surgeries gradually resumed from 27 April, 2020, commencing with the re‐introduction of Category 2 and some important Category 3 procedures (clinically indicated within 365 days), including in vitro fertilisation (IVF) procedures. , The timeline for return to full capacity from 15 May, 2020 was at the discretion of individual jurisdictions.

While national guidelines exist, elective surgery clinical urgency categorisation is governed by individual jurisdictions. Furthermore, during the pandemic, a directive from National Cabinet deemed categorisation to be at the discretion of the healthcare provider. As such, the level of urgency as determined by the treating practitioner may not necessarily have been in line with national, jurisdiction or RANZCOG guidelines, resulting in the possibility of elective medical procedures proceeding against recommendations.

Our study aims to compare the number of selected elective gynaecological and IVF procedures claimed through the Medicare Benefits Schedule (MBS) in Australia between January and June 2019, and January and June 2020. Comparisons may determine the response to recommendations and the type and volume of procedures considered ‘clinically urgent’ during the COVID‐19 pandemic billed via Australia’s national medical payment system.

Materials and Methods

This study was exempt from ethics approval as per the University of New South Wales Human Research Ethics Committee (reference number HC200554). We searched the relevant jurisdiction governmental department websites for policies and guidelines pertaining to elective surgery clinical urgency categorisation. In addition, we utilised the Google search engine for national elective surgery clinical urgency categorisation guidelines using the terms ‘Australia’ AND ‘elective surgery’ AND ‘categorisation’. We also searched for restrictions to elective surgery during the COVID‐19 pandemic using the search terms ‘COVID‐19’ AND ‘Australia’ AND ‘elective surgery’. We repeated this search, adding ‘RANZCOG’ as an additional search term.

We reviewed the MBS item reference lists between January and June 2019, and January and June 2020, and extracted all gynaecological and IVF MBS item numbers. Medicare Item Reports were analysed for the number of gynaecological and IVF procedures claimed in Australia during the same timeframe by item, state and month. We selected groups of item numbers for study based on usual categorisation codes of urgency, and excluded codes where it is not possible to separate data due to acuity of presentation or for malignancy. Data were extracted on miscarriage and termination, and outpatient contraception procedures as comparators that were not included when reporting change in surgical volumes by time period. MBS item numbers were grouped as summarised in Table 1. Numbers of procedures are presented as absolute values without statistical comparison by month or year.

Table 1

Included elective gynaecological and IVF procedures, MBS item numbers and clinical urgency category

Procedure	MBS item numbers	Category
Gynaecology
Vulvoplasty, labioplasty	35533, 35534	Not specified
Prolapse and continence	35568, 35570, 35571, 35572, 35573, 35577, 35578, 35581, 35582, 35585, 35595, 35597, 35599, 35602, 35605, 35684	Stress incontinence and vaginal repair surgery: Category 3 in ACT, Tasmania, Victoria and WA; not specified in NSW Other procedures: not specified
Operative hysteroscopy	35616, 35622, 35623, 35633, 35634, 35635, 35636	NSW: Category 2 Other jurisdictions: Category 3
Benign hysterectomy	35653, 35657, 35661, 35673, 35750, 35753, 35754, 35756	Category 3
Non‐IVF‐related fertility procedures	35694, 35697, 35700, 35703, 35706, 35709, 35710	Tubal dye studies: Category 3 Other procedures: not specified
IVF
Initiation of IVF cycle	13200, 13201	Not specified
Oocyte retrieval	13212	Not specified
Embryo transfer	13215	Not specified
Comparison procedures
Miscarriage and termination	35640, 35643	WA: Category 1 Other jurisdictions: not specified
Outpatient contraception	35502, 35503	35502: Category 2 35503: Category 3

ACT, Australian Capital Territory; IVF, in vitro fertilisation; MBS, Medicare Benefits Schedule; NSW, New South Wales; WA, Western Australia.

Clinical urgency categorisation

The National Elective Surgery Urgency Categorisation Guideline lists common gynaecological procedures and their recommended category. Category 1 procedures are those clinically indicated within 30 days, Category 2 procedures within 90 days and Category 3 procedures within 365 days, with patient factors and the clinical situation taken into account. Western Australia, Tasmania and the Australian Capital Territory provide obligatory policies for clinical urgency categorisation. , , New South Wales (NSW) and Victoria offer guidelines only. , In South Australia (SA), categorisation is at the discretion of the healthcare provider, while no documentation pertaining to clinical urgency categorisation could be located for the Northern Territory (NT). Directives for all jurisdictions apply to the public health system and are not mandated in the private sector. , , , , , The category of included gynaecological and IVF procedures in this study is summarised in Table 1. Categorisation excludes SA and the NT and where the jurisdiction is not stated, the category applies to all.

Results

A total of 41 gynaecological, four IVF and four comparison MBS item numbers, corresponding to 63 340, 116 754 and 132 343 claims, respectively, processed between January and June 2019, and January and June 2020, were included in the analyses. Table 2 details claims processed in the two six‐month periods by type of procedure, while Figure 1 illustrates the percentage difference in the number of procedures processed per month of 2020 compared to the same month of 2019.

Table 2

Number of selected billable elective gynaecological and IVF procedures claimed in Australia in January–June 2019 and January–June 2020

Procedure	Year	Number of procedures
		January	February	March	April	May	June	Total
Gynaecology
Vulvoplasty, labioplasty	2019	27	31	43	35	41	40	217
	2020	39	40	36	23	23	39	200
Prolapse and continence	2019	1415	1586	1674	1404	1762	1498	9339
	2020	1286	1578	1595	676	704	1351	7190
Operative hysteroscopy	2019	2294	2407	2723	2593	3035	2667	15 719
	2020	2161	2600	2818	1704	1857	2464	13 604
Benign hysterectomy	2019	1164	1166	1200	1146	1327	1200	7203
	2020	1090	1194	1255	717	725	1208	6189
Non‐IVF‐related fertility procedures	2019	188	223	217	242	317	336	1523
	2020	328	396	362	257	340	473	2156
IVF
Initiation of IVF cycle	2019	1668	3917	3563	3582	3995	3385	20 110
	2020	1676	3592	3814	1963	2014	4555	17 614
Oocyte retrieval	2019	1845	3508	3274	3360	3781	3359	19 127
	2020	1498	3219	3363	2453	1637	4159	16 329
Embryo transfer	2019	2275	3988	4033	4070	4600	4086	23 052
	2020	1879	4007	4390	3136	2335	4775	20 522
Comparison procedures
Miscarriage and termination	2019	4869	4549	4650	4021	4836	4148	27 073
	2020	4562	4472	4443	3564	3673	3913	24 627
Outpatient contraception	2019	5380	6737	6981	5996	7503	6476	39 073
	2020	5907	7452	7306	5791	6921	8193	41 570

IVF, in vitro fertilisation.

Figure 1

Percentage change in selected billable elective gynaecological and IVF procedures claimed in January–June 2020 compared to January–June 2019. The number of procedures claimed during these periods were extracted from the Medicare Item Reports. Medicare Benefits Schedule item numbers were then grouped by type of procedure. The difference in the number of procedures claimed per month in 2019 and 2020 was expressed as a percentage of the number of procedures claimed in the same month of 2019. IVF, in vitro fertilisation.

The total decrease in included procedures performed in the first half of 2020 compared to the same period of 2019 was −13.71% and −12.56% for gynaecological and IVF item numbers, respectively. Prolapse and continence surgeries, oocyte retrievals and benign hysterectomy had the greatest decrease between the two periods (−23.01%, −14.63% and −14.08%, respectively), while non‐IVF‐related fertility procedures increased (+41.56%).

When comparing paired monthly data, May 2020 reported the greatest downturn compared to 2019 (−43.71% and −51.63% for gynaecological and IVF procedures, respectively, range −60.05% to +7.26% for individual procedure types), while April 2020 reported decreases of −37.69% and −31.42% in gynaecological and IVF procedures, respectively (range −51.85% to +6.20%). IVF procedural volumes in June 2020 exceeded those of 2019 by +24.55%, while gynaecological surgical volumes fell by −3.59% (range −9.81% to +40.77%). The procedures with the greatest paired monthly decrease between 2019 and 2020 were prolapse and continence surgeries claimed in April and May (−51.85% and −60.05%, respectively), and oocyte retrievals claimed in May (−56.70%).

Miscarriage and termination, and outpatient contraception procedures rose by +0.08% during the first six months of 2020 compared to the same period of 2019. Changes of −6.61%, −14.14% and +13.95% in April, May and June 2020, respectively, were documented compared to the corresponding months of 2019.

NSW and Victoria, the states that experienced the highest number of COVID‐19 cases and longest lockdown periods, reported decreases of −8.99% (NSW) and −19.29% (Victoria) in gynaecological, and −12.70% (NSW) and −13.70% (Victoria) in IVF procedures during the two six‐month periods.

Discussion

Suspension of all elective surgeries excepting Category 1 and exceptional Category 2 procedures was announced by National Cabinet from 25 March, 2020. From 27 April, 2020, Category 2 gynaecological surgeries and IVF procedures could be reintroduced, with no Category 3 gynaecological surgeries permitted and volume limits recommended on all surgical procedures. Using April 2020 as the key indicator of the response to elective surgery restrictions, the number of Category 2 and Category 3 procedures should be close to zero. This was not the case, with all procedure types continuing in substantial numbers, albeit reduced compared to the same time interval in the preceding year, with the exception of non‐IVF‐related fertility procedures that increased during this time. This increase is likely due to a shift in outpatient treatments such as contrast ultrasound procedures used for fertility. , There were no specific COVID‐19 restriction guidelines published in Australia for ultrasound practices, with the Australian Society of Ultrasound Medicine recommending that infertility ultrasounds be deferred during this time. ,

The timing of claims submission could be a factor in these figures, since Medicare Item Reports are reported by process date, rather than procedure date. This may affect allocation of procedures by month; however, the effect is likely to be similar for all months. Given the rebound increase in June 2020 claims with the change in regulations, this effect is likely to be minimal. Following the incremental recommendations to elective procedures announced from the end of April 2020, the response to restrictions is more difficult to analyse, with states and territories implementing varied regulatory arrangements.

Classification of procedures such as vulvoplasty, labioplasty, fertility procedures, or surgery for prolapse or continence as Category 1 during the month of April 2020 is difficult to justify. Even if there are truly exceptional circumstances, such cases would not account for the substantial number of procedures claimed in this month. The fact that these continued at the height of the COVID‐19 pandemic when the depth of the crisis and risk posed to patients and staff were unknown suggests that decision making by patients, clinicians and healthcare providers did not take full consideration of the public healthcare issues.

Both National Cabinet and the Fertility Society of Australia recommended cessation of IVF cycle initiation and embryo transfers for the month of April 2020. , , Women already considered ‘in‐cycle’ appropriately were allowed to continue with treatment. , However, a substantial number of cycle initiations and embryo transfers continued to be performed in April 2020, suggesting other contributors to the performance of these procedures during the restrictions.

Hysterectomy and operative hysteroscopy procedures billed during the restricted time interval are higher than anticipated. We excluded MBS item numbers for radical hysterectomy for malignancy and would expect only a small number of those included to be for other cancers. The commonest indications for hysterectomy are leiomyomata (32.4%), abnormal uterine bleeding (16.6%) and prolapse (12.2%), all of which could be considered elective. While unique situations such as severe anaemia or pre‐malignant pathology might occur, these factors would not account for the 717 hysterectomies billed in April 2020 (a −37.43% drop from 2019 for the same time interval).

By comparison and although unaffected by elective surgery restrictions, we observed a decrease in miscarriage and termination procedures, possibly reflecting decreased pregnancy rates and/or desire for pregnancy, or greater numbers of non‐surgical management. Similarly, a small decrease in outpatient contraception procedures was reported in April and May 2020 compared to the same months of 2019, possibly due to decreased face‐to‐face outpatient appointments during this period. Outpatient contraception claims increased substantially in June 2020, which may possibly be due to decreased desire for pregnancy due to the uncertainty of the pandemic.

It is possible that the cessation of elective surgery may have resulted in delayed gynaecological cancer diagnosis in some patients, since occult cancer was diagnosed in 2.23% of hysterectomies and 0.21% of myomectomies in one retrospective series. However, the true effect is unknown at this time, with gynaecological cancer incidences for this period unavailable. These data may be impacted by other factors such as delayed presentation during the pandemic.

This study only includes procedures performed in the private sector, since data pertaining to public procedures are not provided by the Australian Institute of Health and Welfare until the year following the surgical separation. Additionally, the Medicare Item Reports do not contain information regarding billing multiple MBS items for a single surgery and it is possible that non‐urgent procedures presented in this study were performed in conjunction with Category 1 or 2 procedures. However, these are likely to account for only a small proportion of total cases and do not explain the continuance of non‐urgent elective procedures in substantial numbers during this time.

The response to elective surgery restrictions in gynaecology and IVF within Australia is considerably poorer than reported internationally during the pandemic. Elective orthopaedic services in Hong Kong were reduced by 73.5% and approached the directed 80% decrease. Similarly, Germany reported a 75% decrease in both elective and emergency hernia procedures in April 2020 compared to February to June 2019, despite elective surgeries only being postponed between 12 March and 19 April. The poorer Australian response in gynaecology cannot be attributed to the lower number of infectious cases in this country since in the initial stages, the transmissibility and mortality associated with the virus were as unknown here as they were internationally, and our data are a timely reminder as Europe is in the midst of its second wave of infections.

There is no doubt that urgent elective procedures required interventions to be performed, even at the height of the COVID‐19 pandemic. However, the volume of procedures classed as ‘urgent’ and performed during this time is concerning. The maintenance of business to keep staff employed and demand pressures from patients are factors to be considered; however, this must be balanced against the necessity to protect the wider community at a time when the full extent of the COVID‐19 pandemic was unknown. These data suggest there was suboptimal compliance with national recommendations regarding restricting practice. While this lack of self‐regulation may apply to a minority of doctors, careful consideration must be given to more effective measures in future situations to ensure that the health of patients, staff and the public are not compromised.